secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001104659-24-052074
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute to present Phase 2 RIZE overnight hypoglycemia data at PES Annual Meeting
--------------------------------------------------------------------------------

- Dr. Paul Thornton will present poster analyzing overnight hypoglycemia in congenital HI patients on May 4, 2024 at PES meeting.
- Sub-analyses from Phase 2 RIZE study highlight RZ358 benefits during overnight fasting using CGM metrics.
- Previously reported results showed up to ~90% reduction in hypoglycemia events and time at top doses.
- Phase 3 study of RZ358 for congenital hyperinsulinism is currently underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/0001104659-24-052074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924052074/tm2412530d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-052074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer